Testing effectiveness (Phase 2)Study completedNCT06233981
What this trial is testing
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
Who this might be right for
Hepatocellular CarcinomaRadiotherapyTislelizumab+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30